Porvair Sciences, in conjunction with researchers at Swansea University (UK) have written a new technical article entitled 'Chromatrap® 96: a new solid-state platform for high-throughput Chromatin Immunoprecipitation (ChIP)'.
Epigenetics is a fast-growing research area with wide applications, including disease mechanism profiling and personalized medicine strategies. ChIP is crucial to epigenetic research.
Published in the latest issue of Nature Methods (11, 2014) the article provides an introduction to Chromatrap® 96 - a high-throughput ChIP analysis platform and demonstrates how it is able to profile up to 96 transcription factors and epigenetic modifications simultaneously in less than 1 day. The authors** show how the unique solid state platform enables sensitive, selective and reproducible target amplification with excellent signal-to-noise ratios, even from samples as small as 0.1 µg. Further the authors show the compatibility of the platform with automated handling allows for simultaneous investigation of parallel epigenetic landscapes, offering unprecedented ChIP assay flexibility and speed.
To review a copy of this article please visit www.nature.com/nmeth/journal/v11/n9/full/nmeth.f.372.html?WT.ec_id=NMETH-201409. For further information on the Chromatrap® 96 platform please visit www.chromatrap.com or contact Porvair Sciences on +44-1978-666239 or [email protected].
Established in 1992, Porvair Sciences Ltd. has developed internationally recognised expertise in microplate technology and manufacturing serving applications in Drug Discovery, Combinatorial Chemistry, Solid Phase Extraction, Protein Purification, High Throughput Screening, Environmental Analysis, Proteomics and Genomics. Porvair Sciences Ltd. is a wholly owned subsidiary of Porvair plc.
** Article authors: Amy L Beynon, Lesley J Parkes, Matthew L Turner, Steve Knight, Steve Conlan, Lewis Francis & Ben Stocks
Ovarian cancer project shows promise